Navigation Links
Anthera Pharmaceuticals to Present at Annual Piper Jaffray Healthcare Conference
Date:11/27/2013

HAYWARD, Calif., Nov. 27, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, announced today that Paul F. Truex, President and Chief Executive Officer, and May Liu, Senior Vice President of Finance and Administration, will present a corporate update at the 2013 Annual Piper Jaffray Healthcare Conference.

Anthera will present at 4:00PM ET, December 3rd, at the Palace Hotel in New York City.

About Blisibimod

Anthera is developing blisibimod, a selective inhibitor of B-cell activating factor (BAFF), to explore its clinical utility in various autoimmune diseases including systemic lupus erythematosus (SLE) and IgA nephropathy. Blisibimod is a novel fusion protein, or peptibody, and is distinct from an antibody. Anthera owns worldwide rights to blisibimod in all potential indications. BAFF, also known as BLyS (B lymphocyte stimulator), is a tumor necrosis family member and is critical to the development, maintenance and survival of B-cells. B-cells represent a critical component of human immune response to infection and other pathogens. However, abnormal elevations of B-cells and BAFF may lead to an overactive immune response which may damage normal healthy tissues and organ systems. Multiple clinical studies with BAFF antagonists have reported the potential benefit of BAFF inhibitors in treating patients with lupus and rheumatoid arthritis.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases. Anthera's Phase 3 development product candidate, blisibimod, targets elevated levels of B-
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Anthera Pharmaceuticals Reports 2013 Third Quarter Financial Results, Clinical and Regulatory Update
2. Anthera Pharmaceuticals Announces Emerging Data from Phase 2 Open-Label Extension Study to be Presented at the ACR/ARHP 2013 Annual Scientific Meeting
3. Anthera Pharmaceuticals Reports 2013 Second Quarter Financial Results
4. Anthera Announces Initiation of BRIGHT-SC Phase 2 Clinical Study in IgA Nephropathy with Blisibimod
5. Anthera Pharmaceuticals Announces Receipt of Nasdaq Notice
6. Anthera Pharmaceuticals Announces Personnel Changes
7. Anthera Pharmaceuticals to Present at Annual Jefferies Healthcare Conference
8. Anthera Pharmaceuticals Reports 2013 First Quarter Financial Results
9. Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibimod Study
10. Anthera Refinances Existing Debt with New $20 Million Credit Facility and Secures $18.5 Million Committed Equity Financing Facility
11. Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... Chine, 3 juillet 2015 BGI a annoncé ... débit de l,ADN situé à Hong ... l,American College of Pathologists  (Collège des pathologistes américains, ... Hong Kong constituent le premier ... recevoir la certification du CAP en Chine, car ...
(Date:7/2/2015)... July 2, 2015  New product launches are critical ... role in educating thought leaders about new products, Medical ... influence how well a new therapy performs at launch. ... research and consulting leader Best Practices, LLC, critical aspects ... focus on are early stage thought leader (TL) interaction, ...
(Date:7/2/2015)... 2015 Roche,s Bloodhound technology is on ... in hematology testing, according to Kalorama Information.  The ... of its Bloodhound digital cell imaging technology –as ... hematology analyzer – is notable as a ... current leader CellaVision, but also compete more broadly ...
Breaking Medicine Technology:BGI obtient la certification du Collège des pathologistes américains (CAP) 2Medical Affairs Role in Thought Leader Education is Key Success Factor for New Product Launches in the Pharmaceutical Industry 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 3
... cord and other central,nervous system transplants possible, BOSTON, ... Eye Research Institute, an affiliate of Harvard Medical,School, ... into the adult central nervous system. The,study found ... induced by,stem cells) has the ability to break ...
... 26, 2007 - Aeolus,Pharmaceuticals, Inc. (OTCBB:AOLS) announced ... issue of the Journal of Neuroscience a ... and National Jewish,Medical and Research Center demonstrating ... AEOL 11207, demonstrated,neuroprotection in an animal model ...
Cached Medicine Technology:Schepens Scientists Identify Key to Integrating Transplanted Nerve,Cells Into Injured Tissue 2Schepens Scientists Identify Key to Integrating Transplanted Nerve,Cells Into Injured Tissue 3Study Demonstrating Aeolus Compound's Neuroprotection in,Parkinson's Disease Published in the Journal of Neuroscience 2Study Demonstrating Aeolus Compound's Neuroprotection in,Parkinson's Disease Published in the Journal of Neuroscience 3
(Date:7/3/2015)... ... July 03, 2015 , ... Smoothies are all the rage right ... and easily accessible, quality ingredients. Aurora Natural is proud to introduce a new line ... of fiber, protein, antioxidants, vitamins and minerals! , Aurora is offering a variety of ...
(Date:7/3/2015)... (PRWEB) , ... July 03, 2015 , ... Jennifer Renee ... First Choice Emergency Room , the largest network of independent freestanding emergency rooms in ... facility medical director of our Sienna Plantation facility,” said Executive Medical Director of First ...
(Date:7/3/2015)... ... July 03, 2015 , ... " Selfie on a Stick ... the latest and coolest technology products available to consumers. Amanda Forstrom, a technology expert ... selfie sticks are great for documenting memories. , Almost every smartphone has an incredibly ...
(Date:7/3/2015)... , ... July 03, 2015 , ... Every year, One-to-1 ... Train-a-Thon where they provide members of the Red Deer community with free fitness training ... of fitness training, games, food, events and entertainment raised thousands of charity dollars and ...
(Date:7/2/2015)... ... 2015 , ... sweetFrog Enterprises, LLC. is pleased to announce the opening of ... located in Mississippi. The premium frozen yogurt chain was listed as #22 on the ... 104 Railroad Avenue, New Albany, MS 38652, will have a grand opening event on ...
Breaking Medicine News(10 mins):Health News:Aurora Product, Inc. Announces An Original New Line: Smoothie Fixins’ 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 3Health News:Learn How to Take Selfies like Kendall Jenner 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 3Health News:sweetfrog Opens First Location in Mississippi 2
... prostate cancer treated with a specialized type of ... fewer gastrointestinal complications compared to patients treated with ... study presented November 1, 2010, at the 52nd ... Oncology (ASTRO). , "With survivors living ...
... invasive bladder cancer allows 67 percent of people to be ... This compares to 54 percent of people who receive radiation ... presented at the plenary session, November 1, 2010, at the ... (ASTRO). , "The trial shows that this treatment offers improved ...
... October 25, 2010 The Life Sciences Discovery Fund (LSDF) ... Corporation (NASDAQ: OMER) to discover, develop, and commercialize new ... successful generation of proceeds through partnering and the sales ... the grant would be establishment of a new non-profit ...
... HealthDay Reporter , MONDAY, Oct. 25 (HealthDay News) -- New ... will start sleeping through the night between 2 and 4 ... however, is for the baby,s eight hours of slumber to ... "The most rapid changes in infant sleep were found ...
... immune system genes A team of ... Cambridge, United Kingdom, has shed new light on genetic ... common disorders of pregnancy, specifically recurrent miscarriage, preeclampsia, and ... initiation of a successful pregnancy is the invasion of ...
... pathway that, when blocked, significantly decreases the spread of ... at The University of Texas MD Anderson Children,s Cancer ... in mice decreased metastases in the lungs 15-fold. The ... Sunday in an oral presentation at the 42nd Congress ...
Cached Medicine News:Health News:Highly targeted radiation technique minimizes side effects of prostate cancer treatment 2Health News:Chemotherapy plus radiation prevents bladder cancer recurrences 2Health News:Life Sciences Discovery Fund to support drug discovery, foster new R&D initiative 2Health News:Life Sciences Discovery Fund to support drug discovery, foster new R&D initiative 3Health News:Most Babies Start Sleeping Through Night at 2 to 4 Months 2Health News:Most Babies Start Sleeping Through Night at 2 to 4 Months 3Health News:JCI table of contents: Oct. 25, 2010 2Health News:JCI table of contents: Oct. 25, 2010 3Health News:JCI table of contents: Oct. 25, 2010 4Health News:JCI table of contents: Oct. 25, 2010 5Health News:JCI table of contents: Oct. 25, 2010 6Health News:JCI table of contents: Oct. 25, 2010 7Health News:JCI table of contents: Oct. 25, 2010 8Health News:JCI table of contents: Oct. 25, 2010 9Health News:Researchers find pathway that drives spread of pediatric bone cancer in preclinical studies 2
CDIs 2-Panel Abdominal Binders are designed with a foam backing which provides comfort, support and compression without slippage....
Male Compression Vests...
Male Compression Vest, Front Closure...
Ideal for breast compression with adjustable hook and eye closure....
Medicine Products: